Wealth Enhancement Advisory Services LLC Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Wealth Enhancement Advisory Services LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,772 shares of the biopharmaceutical company's stock after selling 43,239 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Gilead Sciences were worth $25,843,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. HHM Wealth Advisors LLC grew its stake in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new stake in Gilead Sciences during the 4th quarter worth about $28,000. Crews Bank & Trust purchased a new stake in Gilead Sciences during the 4th quarter worth about $31,000. Stephens Consulting LLC lifted its holdings in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 260 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC lifted its holdings in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

GILD traded up $0.42 on Tuesday, hitting $109.33. 9,875,443 shares of the company traded hands, compared to its average volume of 7,729,170. The company has a 50 day moving average of $105.45 and a 200-day moving average of $101.10. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $136.00 billion, a PE ratio of 295.49, a PEG ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm's revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.32) EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.89%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,929 shares of company stock worth $6,748,980. Company insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Oppenheimer decreased their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Royal Bank of Canada lifted their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Morgan Stanley lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.